Enzo Biochem (ENZ) Downgraded by TheStreet

TheStreet cut shares of Enzo Biochem (NYSE:ENZ) from a c- rating to a d+ rating in a research report sent to investors on Wednesday.

Separately, ValuEngine upgraded shares of Enzo Biochem from a sell rating to a hold rating in a research report on Monday, July 16th.

Enzo Biochem stock opened at $3.28 on Wednesday. Enzo Biochem has a 12-month low of $3.27 and a 12-month high of $10.47.

Enzo Biochem (NYSE:ENZ) last released its earnings results on Tuesday, October 16th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). Enzo Biochem had a negative net margin of 9.86% and a negative return on equity of 13.25%. The company had revenue of $24.46 million for the quarter.

A number of hedge funds have recently made changes to their positions in ENZ. A.R.T. Advisors LLC bought a new stake in Enzo Biochem during the 1st quarter valued at $115,000. Hartford Investment Management Co. bought a new stake in Enzo Biochem during the 2nd quarter valued at $118,000. Highbridge Capital Management LLC increased its stake in Enzo Biochem by 50.3% during the 1st quarter. Highbridge Capital Management LLC now owns 38,340 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 12,836 shares in the last quarter. Alps Advisors Inc. bought a new stake in Enzo Biochem during the 2nd quarter valued at $324,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Enzo Biochem during the 2nd quarter valued at $400,000. Institutional investors and hedge funds own 67.75% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

See Also: Why do companies issue stock splits?

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply